ArticleScientific reports2025
An open source, PCR based, point-of-care testing platform.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Towards practical point-of-care quick, ubiquitous, integrated, cost-efficient molecular diagnostic Kit (QUICK) PCR for future pandemic response.Microsystems & nanoengineering · 2025Review
- Integration of Point-of-Care Technology in the Decoding Process of Single Nucleotide Polymorphism for Healthcare ApplicationMicromachines · 2025Review
- Democratization of Point-of-Care Viral Biosensors: Bridging the Gap from Academia to the Clinic.Biosensors · 2025Review
- Comprehensive Review on Viral RNA Extraction Strategies for Enhanced Molecular Diagnostics.Interdisciplinary perspectives on infectious diseases · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In recent years, point-of-care nucleic acid testing had played an important role in the diagnosis of infectious diseases. Despite its advantages, current point-of-care testing (POCT) platforms were all closed, which hindered researchers from quickly validating the performance of customized reagents. Incompatibility and repeated development of different POCT devices also resulted in the waste of medical resources. In this article, a rotating cartridge with a detachable reagent rack was developed, which provided an open platform in conjunction with a programmable POCT instrument. The system had been confirmed to effectively detect the HPV sample with a concentration of 1000 copies per milliliter and the novel coronavirus nucleic acid control dilution with a concentration of 200 copies per milliliter within 1 h. The cartridge could detect six targets simultaneously and cost less than ten dollars. The square of the correlation coefficients of the fitting line between the dye concentration and the fluorescence intensity all exceeded 0.99. The coefficient of variation (CV) for testing one sample with multiple cartridges or instruments was under 3%, confirming the stability and reliability of system performance. Results of clinical testing further verified its ability to detect multiple viruses, including novel coronavirus, influenza and human papillomavirus. Compared with standard results, the sensitivity reached 100% in the detection of multiple respiratory viruses and HPV viruses while the specificity was above 98% for all targets. The area under the curve (AUC) values for all receiver operating characteristic (ROC) curves exceeded 0.98. These results indicated that this platform had excellent performances and provided a competitive solution for low-cost, open point-of-care nucleic acid testing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.